ZAI LAB LIMITED Amortization of Debt Issuance Costs
ZAI LAB LIMITED (ZLAB) reported Amortization of Debt Issuance Costs of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-06
- ZAI LAB LIMITED amortization of debt issuance costs for the quarter ending 2025-12-31 was $0.00.
- ZAI LAB LIMITED amortization of debt issuance costs for the quarter ending 2025-09-30 was $90.00K.
- ZAI LAB LIMITED amortization of debt issuance costs for the quarter ending 2025-06-30 was $104.00K.
- ZAI LAB LIMITED amortization of debt issuance costs for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- ZAI LAB LIMITED amortization of debt issuance costs for fiscal 2025 was $194.00K, a 72.29% decline from fiscal 2024.
- ZAI LAB LIMITED amortization of debt issuance costs for fiscal 2024 was $700.00K.
- ZAI LAB LIMITED amortization of debt issuance costs for fiscal 2023 was $0.00.
- ZAI LAB LIMITED amortization of debt issuance costs for fiscal 2022 was $0.00.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $90.00K derived: sum of 2 quarters · filed 2026-02-26 | $194.00K derived: sum of 3 quarters · filed 2026-08-06 | $194.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $194.00K derived: sum of 2 quarters · filed 2026-08-06 | $194.00K 10-Q · filed 2025-11-06 | $194.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $104.00K 10-Q · filed 2026-08-06 | $104.00K derived: sum of 3 quarters · filed 2026-08-06 | $104.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $700.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $700.00K 10-Q · filed 2025-11-06 | $700.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $700.00K 10-Q · filed 2025-08-07 | $700.00K derived: sum of 3 quarters · filed 2026-02-26 | $700.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $700.00K 10-Q · filed 2025-05-08 | $700.00K derived: sum of 2 quarters · filed 2026-02-26 | $700.00K derived: sum of 3 quarters · filed 2026-02-26 | $700.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |